CUSIP 24823R105 · who reports it, how much, and how much it matters to them
22 of the 720 hedge fund managers we track reported shares of Denali Therapeutics Inc. (Nasdaq: DNLI) on Form 13F for 30 June 2026. Between them they reported USD 439m. The largest position belongs to Holocene Advisors, at USD 100m. The manager with the most riding on it is Crestline Management, where it is 91.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Holocene Advisors2 funds on PPLI.com | USD 100m | 0.2% |
| 2 | Baker Bros. Advisors2 funds on PPLI.com | USD 96m | 0.5% |
| 3 | Casdin Capital3 funds on PPLI.com | USD 53m | 2.6% |
| 4 | Crestline Management45 funds on PPLI.com | USD 49m | 91.9% |
| 5 | Artisan Partners1 fund on PPLI.com | USD 31m | 0.1% |
| 6 | Millennium Management6 funds on PPLI.com | USD 29m | 0.0% |
| 7 | Dafna Capital Management6 funds on PPLI.com | USD 19m | 3.6% |
| 8 | Cercano Management5 funds on PPLI.com | USD 16m | 2.1% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 14m | 0.0% |
| 10 | Exoduspoint Capital Management7 funds on PPLI.com | USD 8.7m | 0.1% |
| 11 | Masters Capital Management4 funds on PPLI.com | USD 5.1m | 0.1% |
| 12 | Burkehill Global Management5 funds on PPLI.com | USD 5.1m | 0.2% |
| 13 | Hudson Bay Capital Management8 funds on PPLI.com | USD 3.3m | 0.0% |
| 14 | PFM Health Sciences3 funds on PPLI.com | USD 2.6m | 0.2% |
| 15 | Citadel Advisors32 funds on PPLI.com | USD 1.7m | 0.0% |
| 16 | Engineers Gate Manager1 fund on PPLI.com | USD 1.5m | 0.0% |
| 17 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.1m | 0.0% |
| 18 | Jain Global1 fund on PPLI.com | USD 989,000 | 0.0% |
| 19 | Capstone Investment Advisors25 funds on PPLI.com | USD 539,000 | 0.0% |
| 20 | Graham Capital Management18 funds on PPLI.com | USD 403,000 | 0.0% |
| 21 | Bayforest Capital1 fund on PPLI.com | USD 294,000 | 0.3% |
| 22 | Graticule Asia Macro Advisors8 funds on PPLI.com | USD 56,738 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Crestline Management | USD 49m | 91.9% |
| 2 | Dafna Capital Management | USD 19m | 3.6% |
| 3 | Casdin Capital | USD 53m | 2.6% |
| 4 | Cercano Management | USD 16m | 2.1% |
| 5 | Baker Bros. Advisors | USD 96m | 0.5% |
| 6 | Bayforest Capital | USD 294,000 | 0.3% |
| 7 | Holocene Advisors | USD 100m | 0.2% |
| 8 | PFM Health Sciences | USD 2.6m | 0.2% |
| 9 | Burkehill Global Management | USD 5.1m | 0.2% |
| 10 | Masters Capital Management | USD 5.1m | 0.1% |
Denali Therapeutics Inc. trades under the symbol DNLI on the Nasdaq. Its CUSIP, the code used on Form 13F, is 24823R105.
22 of the 720 hedge fund managers PPLI.com tracks reported Denali Therapeutics Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Holocene Advisors (USD 100m), Baker Bros. Advisors (USD 96m), Casdin Capital (USD 53m), Crestline Management (USD 49m) and Artisan Partners (USD 31m).
22 managers in our coverage reported it, and between them they run 277 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Crestline Management, where the position was 91.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Denali Therapeutics Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.